Janssen acquires rights to Hemera’s investigational eye-disorder gene therapy
HMR59 is being developed to administer as a one-time, outpatient and intravitreal injection to protect vision in patients with geographic atrophy, a late-stage and severe form of age-related
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.